发现不含3-硝基毒性基团的强效茚并异喹啉拓扑异构酶I抑制剂。
Discovery of potent indenoisoquinoline topoisomerase I poisons lacking the 3-nitro toxicophore.
作者信息
Beck Daniel E, Abdelmalak Monica, Lv Wei, Reddy P V Narasimha, Tender Gabrielle S, O'Neill Elizaveta, Agama Keli, Marchand Christophe, Pommier Yves, Cushman Mark
机构信息
†Department of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, and the Purdue Center for Cancer Research, Purdue University, 575 Stadium Mall Drive, West Lafayette, Indiana 47907, United States.
‡Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, NCI-Frederick, Frederick, Maryland 21702, United States.
出版信息
J Med Chem. 2015 May 14;58(9):3997-4015. doi: 10.1021/acs.jmedchem.5b00303. Epub 2015 Apr 24.
Abstract
3-Nitroindenoisoquinoline human topoisomerase IB (Top1) poisons have potent antiproliferative effects on cancer cells. The undesirable nitro toxicophore could hypothetically be replaced by other functional groups that would retain the desired biological activities and minimize potential safety risks. Eleven series of indenoisoquinolines bearing 3-nitro bioisosteres were synthesized. The molecules were evaluated in the Top1-mediated DNA cleavage assay and in the National Cancer Institute's 60 cell line cytotoxicity assay. The data reveal that fluorine and chlorine may substitute for the 3-nitro group with minimal loss of Top1 poisoning activity. The new information gained from these efforts can be used to design novel indenoisoquinolines with improved safety.
摘要
3-硝基茚并异喹啉类人拓扑异构酶IB（Top1）抑制剂对癌细胞具有强大的抗增殖作用。理论上，不良的硝基毒性基团可以被其他官能团取代，这些官能团将保留所需的生物活性并将潜在的安全风险降至最低。合成了11个带有3-硝基生物电子等排体的茚并异喹啉系列。这些分子在Top1介导的DNA切割试验和美国国立癌症研究所的60细胞系细胞毒性试验中进行了评估。数据表明，氟和氯可以替代3-硝基，而Top1抑制活性的损失最小。这些研究获得的新信息可用于设计安全性更高的新型茚并异喹啉类化合物。
相似文献
1
Discovery of potent indenoisoquinoline topoisomerase I poisons lacking the 3-nitro toxicophore.发现不含3-硝基毒性基团的强效茚并异喹啉拓扑异构酶I抑制剂。
J Med Chem. 2015 May 14;58(9):3997-4015. doi: 10.1021/acs.jmedchem.5b00303. Epub 2015 Apr 24.
2
Synthesis and biological evaluation of new fluorinated and chlorinated indenoisoquinoline topoisomerase I poisons.新型氟化和氯化茚并异喹啉拓扑异构酶I抑制剂的合成与生物学评价
Bioorg Med Chem. 2016 Apr 1;24(7):1469-79. doi: 10.1016/j.bmc.2016.02.015. Epub 2016 Feb 9.
3
Azaindenoisoquinolines as topoisomerase I inhibitors and potential anticancer agents: a systematic study of structure-activity relationships.吖啶并异喹啉类作为拓扑异构酶 I 抑制剂和潜在的抗癌剂：构效关系的系统研究。
J Med Chem. 2012 Feb 23;55(4):1682-97. doi: 10.1021/jm201512x. Epub 2012 Feb 13.
4
Synthesis and biological evaluation of indenoisoquinolines that inhibit both tyrosyl-DNA phosphodiesterase I (Tdp1) and topoisomerase I (Top1).吲哚异喹啉类抑制剂的合成与生物评价，该抑制剂既能抑制酪氨酰-DNA 磷酸二酯酶 I（Tdp1），又能抑制拓扑异构酶 I（Top1）。
J Med Chem. 2013 Jan 10;56(1):182-200. doi: 10.1021/jm3014458. Epub 2012 Dec 21.
5
Nitrated indenoisoquinolines as topoisomerase I inhibitors: a systematic study and optimization.硝化茚并异喹啉类作为拓扑异构酶I抑制剂：一项系统性研究与优化
J Med Chem. 2007 Sep 6;50(18):4419-30. doi: 10.1021/jm070361q. Epub 2007 Aug 15.
6
Synthesis and biological evaluations of novel indenoisoquinolines as topoisomerase I inhibitors.新型吲哚异喹啉类化合物的合成及拓扑异构酶 I 抑制活性评价。
Bioorg Med Chem Lett. 2012 Jan 15;22(2):1276-81. doi: 10.1016/j.bmcl.2011.10.019. Epub 2011 Oct 24.
7
Alcohol-, diol-, and carbohydrate-substituted indenoisoquinolines as topoisomerase I inhibitors: investigating the relationships involving stereochemistry, hydrogen bonding, and biological activity.醇、二醇和碳水化合物取代的茚并异喹啉类化合物作为拓扑异构酶 I 抑制剂：立体化学、氢键和生物活性关系的研究。
J Med Chem. 2011 Jul 28;54(14):4937-53. doi: 10.1021/jm101338z. Epub 2011 Jun 28.
8
Synthesis of new indeno[1,2-c]isoquinolines: cytotoxic non-camptothecin topoisomerase I inhibitors.新型茚并[1,2-c]异喹啉的合成：细胞毒性非喜树碱类拓扑异构酶I抑制剂
J Med Chem. 2000 Oct 5;43(20):3688-98. doi: 10.1021/jm000029d.
9
Synthesis and biological evaluation of bisindenoisoquinolines as topoisomerase I inhibitors.双茚并异喹啉作为拓扑异构酶I抑制剂的合成及生物学评价
J Med Chem. 2006 Aug 24;49(17):5129-40. doi: 10.1021/jm060046o.
10
Optimization of the indenone ring of indenoisoquinoline topoisomerase I inhibitors.茚并异喹啉拓扑异构酶I抑制剂中茚酮环的优化
J Med Chem. 2007 Sep 6;50(18):4388-404. doi: 10.1021/jm070307+. Epub 2007 Aug 4.
引用本文的文献
1
Discovery and optimization of a guanylhydrazone-based small molecule to replace bFGF for cell culture applications.基于脒腙的小分子替代碱性成纤维细胞生长因子用于细胞培养应用的发现与优化。
Biochem Biophys Rep. 2025 Jul 21;43:102167. doi: 10.1016/j.bbrep.2025.102167. eCollection 2025 Sep.
2
Synthesis of nicotinimidamides a tandem CuAAC/ring-cleavage /cyclization/oxidation four-component reaction and their cytotoxicity.烟酰胺类似物的合成——一种串联的铜催化的叠氮-炔环加成反应/环裂解/环化/氧化四组分反应及其细胞毒性
RSC Adv. 2024 Aug 16;14(35):25844-25851. doi: 10.1039/d4ra04918g. eCollection 2024 Aug 12.
3
Differential Effect of 4-Benzo[] [1, 3]oxazines on the Proliferation of Breast Cancer Cell Lines.4-苯并[1,3]恶嗪类化合物对乳腺癌细胞系增殖的差异影响。
Curr Med Chem. 2024;31(38):6306-6318. doi: 10.2174/0109298673292365240422104456.
4
Natural Compounds as Therapeutic Agents: The Case of Human Topoisomerase IB.天然化合物作为治疗剂：以人类拓扑异构酶 IB 为例。
Int J Mol Sci. 2021 Apr 16;22(8):4138. doi: 10.3390/ijms22084138.
5
Copper Complexes as Anticancer Agents Targeting Topoisomerases I and II.作为靶向拓扑异构酶I和II的抗癌剂的铜配合物
Cancers (Basel). 2020 Oct 5;12(10):2863. doi: 10.3390/cancers12102863.
6
The Trifluoromethyl Group as a Bioisosteric Replacement of the Aliphatic Nitro Group in CB Receptor Positive Allosteric Modulators.三氟甲基作为 CB 受体正向变构调节剂中脂族硝基的生物等排体取代基。
J Med Chem. 2019 May 23;62(10):5049-5062. doi: 10.1021/acs.jmedchem.9b00252. Epub 2019 May 14.
7
Design and Synthesis of Chlorinated and Fluorinated 7-Azaindenoisoquinolines as Potent Cytotoxic Anticancer Agents That Inhibit Topoisomerase I.作为抑制拓扑异构酶I的强效细胞毒性抗癌剂的氯化和氟化7-氮杂二氢异喹啉的设计与合成
J Med Chem. 2017 Jul 13;60(13):5364-5376. doi: 10.1021/acs.jmedchem.6b01870. Epub 2017 Jun 28.
8
Sophoridinol derivative 05D induces tumor cells apoptosis by topoisomerase1-mediated DNA breakage.槐定醇衍生物05D通过拓扑异构酶1介导的DNA断裂诱导肿瘤细胞凋亡。
Onco Targets Ther. 2016 May 11;9:2805-17. doi: 10.2147/OTT.S103671. eCollection 2016.
9
Investigation of the Structure-Activity Relationships of Aza-A-Ring Indenoisoquinoline Topoisomerase I Poisons.氮杂 - A - 环茚并异喹啉拓扑异构酶I抑制剂的构效关系研究
J Med Chem. 2016 Apr 28;59(8):3840-53. doi: 10.1021/acs.jmedchem.6b00003. Epub 2016 Apr 12.
10
Synthesis and biological evaluation of new fluorinated and chlorinated indenoisoquinoline topoisomerase I poisons.新型氟化和氯化茚并异喹啉拓扑异构酶I抑制剂的合成与生物学评价
Bioorg Med Chem. 2016 Apr 1;24(7):1469-79. doi: 10.1016/j.bmc.2016.02.015. Epub 2016 Feb 9.
本文引用的文献
1
Tyrosyl-DNA-phosphodiesterases (TDP1 and TDP2).酪氨酰-DNA磷酸二酯酶（TDP1和TDP2）。
DNA Repair (Amst). 2014 Jul;19:114-29. doi: 10.1016/j.dnarep.2014.03.020. Epub 2014 May 22.
2
Design, synthesis, and biological evaluation of O-2-modified indenoisoquinolines as dual topoisomerase I-tyrosyl-DNA phosphodiesterase I inhibitors.O-2-修饰的茚并异喹啉作为双拓扑异构酶I-酪氨酰-DNA磷酸二酯酶I抑制剂的设计、合成及生物学评价
J Med Chem. 2014 May 22;57(10):4324-36. doi: 10.1021/jm500294a. Epub 2014 May 6.
3
Synthesis and biological evaluation of new carbohydrate-substituted indenoisoquinoline topoisomerase I inhibitors and improved syntheses of the experimental anticancer agents indotecan (LMP400) and indimitecan (LMP776).新型糖基取代的苯并异喹啉拓扑异构酶 I 抑制剂的合成与生物评价，以及实验性抗癌药物 LMP400（吲替康）和 LMP776（伊立替康）的改进合成。
J Med Chem. 2014 Feb 27;57(4):1495-512. doi: 10.1021/jm401814y. Epub 2014 Feb 11.
4
Optimization of the lactam side chain of 7-azaindenoisoquinoline topoisomerase I inhibitors and mechanism of action studies in cancer cells.优化 7-氮杂吲哚并喹啉拓扑异构酶 I 抑制剂的内酰胺侧链及其在癌细胞中的作用机制研究。
J Med Chem. 2014 Feb 27;57(4):1289-98. doi: 10.1021/jm401471v. Epub 2014 Feb 6.
5
Phenylpyrazolo[1,5-a]quinazolin-5(4H)-one: a suitable scaffold for the development of noncamptothecin topoisomerase I (Top1) inhibitors.苯基吡唑并[1,5-a]喹唑啉-5(4H)-酮：一种用于开发非喜树碱拓扑异构酶 I（Top1）抑制剂的合适支架。
J Med Chem. 2013 Sep 26;56(18):7458-62. doi: 10.1021/jm400932c. Epub 2013 Sep 16.
6
Toxoflavins and deazaflavins as the first reported selective small molecule inhibitors of tyrosyl-DNA phosphodiesterase II.作为首个报道的酪氨酰-DNA 磷酸二酯酶 II 的选择性小分子抑制剂，托伐黄素和去氮杂黄素。
J Med Chem. 2013 Aug 22;56(16):6352-70. doi: 10.1021/jm400568p. Epub 2013 Jul 31.
7
Design, synthesis, and biological evaluation of indenoisoquinoline rexinoids with chemopreventive potential.设计、合成及具有化学预防潜力的吲哚异喹啉雷帕霉素类化合物的生物评价。
J Med Chem. 2013 Mar 28;56(6):2581-605. doi: 10.1021/jm400026k. Epub 2013 Mar 8.
8
Synthesis and biological evaluation of indenoisoquinolines that inhibit both tyrosyl-DNA phosphodiesterase I (Tdp1) and topoisomerase I (Top1).吲哚异喹啉类抑制剂的合成与生物评价，该抑制剂既能抑制酪氨酰-DNA 磷酸二酯酶 I（Tdp1），又能抑制拓扑异构酶 I（Top1）。
J Med Chem. 2013 Jan 10;56(1):182-200. doi: 10.1021/jm3014458. Epub 2012 Dec 21.
9
Principles and applications of halogen bonding in medicinal chemistry and chemical biology.卤键在药物化学和化学生物学中的原理与应用。
J Med Chem. 2013 Feb 28;56(4):1363-88. doi: 10.1021/jm3012068. Epub 2013 Jan 3.
10
5-Arylidenethioxothiazolidinones as inhibitors of tyrosyl-DNA phosphodiesterase I.5-芳亚甲基硫代噻唑烷酮类作为酪氨酰 DNA 磷酸二酯酶 I 的抑制剂。
J Med Chem. 2012 Oct 25;55(20):8671-84. doi: 10.1021/jm3008773. Epub 2012 Oct 8.
Zotero 插件